Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics

Therapeutic Drug Monitoring

Volumn 22, Issue 1, 2000, Pages 114-117

  Dahl, Marja Liisa ^a   Sjöqvist, Folke ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antidepressants; Neuroleptics; Pharmacogenetics

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DESIPRAMINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIDAZOLAM; NEFAZODONE; NEUROLEPTIC AGENT; NORCITALOPRAM; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; UNINDEXED DRUG; VENLAFAXINE; ZUCLOPENTHIXOL;

DEMETHYLATION; DEPRESSION; DRUG METABOLISM; DRUG MONITORING; GENOTYPE; HUMAN; HYDROXYLATION; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE;

EID: 0033973925     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200002000-00024     Document Type: Review

References (25)

1. Gram LP. Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet 1977;237-251
2. Sjöqvist F, Bertilsson L, Åsberg M. Monitoring tricyclic antidepressants. Ther Drug Monit 1980;25:85-93
3. Sjöqvist F. Pharmacogenetic factors in the metabolism of tricyclic antidepressants and some neuroleptics. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992: 689-695
4. Bertilsson L, Dahl ML. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996;5:200-223
5. Alexanderson B, Price-Evans DA, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969;2:764-768
6. Alexanderson B. Prediction of steady-state plasma levels of nortiptyline from single oral dose kinetics: A study in twins. Br J Clin Pharmacol 1973;6:44-53
7. Åsberg M, Price-Evans D, Sjöqvist F. Genetic control of nortriptyline kinetics in man - a study of relatives of propositi with high plasma concentrations. J Med Genet 1971;8:129-135
8. Mahgoub H, Idle JB, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-586
9. Mellström B, Bertilsson L, Säwe J, Schültz H-D, Sjöqvist F. E-and Z-hydroxylation of nortriptyline - relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981;30:189-193
10. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-532
11. Ingelman-Sundberg M, Oscars on M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20:342-349
12. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-558
13. Dahl M-L, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992:51:12-17
14. Brosen K, Nielsen PN, Brusgaard K, Gram LF, Skjodt K. CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 1994:47:221-225.
15. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-459
16. Dahl M-L, Yue QY, Roh HK, et al. Genetic analysis of.the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995;5:159-164
17. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjö qvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274:516-520
18. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90: 11825-11829
19. Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985;7:478-480.
20. Bertilsson L, Dahl M-L, Sjöqvist F et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993;341:63
21. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57: 265-269
22. Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady-state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology, 1999:147:300-305.
23. Dalén P, Frengell C, Dahl M-L, Sjöqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997;19:543-544
24. Jerling M, Dahl M-L, Åberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996;59:423-428
25. Mihara K, Otani K, Tybring G, Dahl M-L, Bertilsson L, Kaneko S. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharm 1997; 17:467-471